Payment overview · 2025
General Payments
$143.96
9 reported records · 8 companies
Healthcare provider profile · identity verified
Nathan D Granger, MD
Allopathic & Osteopathic Physicians|Family Medicine · KANSAS CITY, MO · NPI 1144288002
Verified facts
What the public records show
CMS Open Payments records show Nathan D Granger, MD received $143.96 in general payments during 2025 across 9 reported records.
Amgen Inc. accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.65 | 20.6% | 2 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $21.74 | 15.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $18.53 | 12.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.36 | 12.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.92 | 10.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.29 | 9.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.83 | 9.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.64 | 9.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $143.96 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.65 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.65 | 2 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
58 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 509 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 461 | 143 |
| Atorvastatin Calcium | Atorvastatin Calcium | 440 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 366 | 105 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 346 | 71 |
| Losartan Potassium | Losartan Potassium | 342 | 97 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 329 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 314 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 82 |
| Omeprazole | Omeprazole | 270 | 81 |
| Gabapentin | Gabapentin | 243 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 234 | 73 |
| Carvedilol | Carvedilol | 226 | 56 |
| Metformin Hcl Er | Metformin Hcl | 225 | 70 |
| Lisinopril | Lisinopril | 202 | 58 |
| Sertraline Hcl | Sertraline Hcl | 179 | 51 |
| Furosemide | Furosemide | 170 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 72 |
| Irbesartan | Irbesartan | 147 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 144 | 61 |
| Ezetimibe | Ezetimibe | 143 | 43 |
| Tramadol Hcl | Tramadol Hcl | 142 | 37 |
| Simvastatin | Simvastatin | 140 | 37 |
| Potassium Chloride | Potassium Chloride | 136 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 36 |
| Eliquis | Apixaban | 129 | 29 |
| Allopurinol | Allopurinol | 128 | 39 |
| Finasteride | Finasteride | 127 | 37 |
| Alprazolam | Alprazolam | 120 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 28 |
| Glimepiride | Glimepiride | 106 | 30 |
| Metformin Hcl | Metformin Hcl | 104 | 34 |
| Meloxicam | Meloxicam | 99 | 31 |
| Donepezil Hcl | Donepezil Hcl | 94 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 24 |
| Pregabalin | Pregabalin | 92 | 25 |
| Cefuroxime | Cefuroxime Axetil | 88 | 71 |
| Oxycodone Hcl | Oxycodone Hcl | 85 | 15 |
| Warfarin Sodium | Warfarin Sodium | 85 | 15 |
| Azithromycin | Azithromycin | 81 | 66 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 24 |
| Celecoxib | Celecoxib | 78 | 33 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 77 | 50 |
| Ibandronate Sodium | Ibandronate Sodium | 75 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 21 |
| Lorazepam | Lorazepam | 68 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 26 |
| Montelukast Sodium | Montelukast Sodium | 66 | 17 |
| Ozempic | Semaglutide | 62 | 21 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 58 | 58 |
| Famotidine | Famotidine | 58 | 20 |
| Ketoconazole | Ketoconazole | 58 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | suppressed |
| Cephalexin | Cephalexin | 56 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 33 |
| Bupropion Xl | Bupropion Hcl | 52 | 17 |
| Trazodone Hcl | Trazodone Hcl | 52 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 19 |
| Fenofibrate | Fenofibrate | 42 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 11 |
| Lovastatin | Lovastatin | 40 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 11 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Valsartan | Valsartan | 37 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 36 | 35 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 16 |
| Torsemide | Torsemide | 35 | 11 |
| Fluconazole | Fluconazole | 34 | 20 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | 13 |
| Trospium Chloride | Trospium Chloride | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | 11 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Zaleplon | Zaleplon | 25 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 17 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Prednisone | Prednisone | 24 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 20 |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 16 |
| Temazepam | Temazepam | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 14 | 11 |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Ramipril | Ramipril | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Imiquimod | Imiquimod | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $143.96 · 9 records | Amgen Inc. | FREESTYLE LIBRE 3, IBSRELA, INSPIRE, JOURNAVX, MOUNJARO, OTEZLA, Paradise Ultrasound Renal Denervation System, REPATHA, TRELEGY ELLIPTA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error